Intech Investment Management LLC Buys New Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

Intech Investment Management LLC purchased a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,688 shares of the medical instruments supplier’s stock, valued at approximately $84,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tidal Investments LLC bought a new position in shares of OraSure Technologies during the 1st quarter valued at approximately $116,000. SG Americas Securities LLC lifted its position in OraSure Technologies by 46.4% during the second quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock valued at $73,000 after purchasing an additional 5,431 shares during the last quarter. Shikiar Asset Management Inc. purchased a new position in shares of OraSure Technologies in the 2nd quarter worth $96,000. Assenagon Asset Management S.A. increased its holdings in shares of OraSure Technologies by 74.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 163,542 shares of the medical instruments supplier’s stock worth $697,000 after buying an additional 69,625 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after buying an additional 605,324 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 4th.

OraSure Technologies Stock Up 1.8 %

OSUR stock opened at $3.91 on Monday. OraSure Technologies, Inc. has a twelve month low of $3.72 and a twelve month high of $8.45. The stock has a market capitalization of $291.65 million, a price-to-earnings ratio of 26.07 and a beta of 0.03. The firm’s fifty day simple moving average is $4.04 and its two-hundred day simple moving average is $4.25.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $39.92 million for the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm’s revenue was down 55.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.27 EPS. As a group, equities research analysts expect that OraSure Technologies, Inc. will post -0.07 EPS for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.